Genmab A/S (GMAB) Q2 2022 Earnings Call Transcript

For the period ending June 30, 2022

August 10, 2022 12:00 p.m. ET

Prepared Remarks

Questions and Answers

Call Participants

Prepared Remarks:

Operator

Hello, and welcome to the Genmab Q2 2022 Conference Call. Throughout the call, all participants will be in listen-only mode and afterwards, there will be a question-and-answer session. Just to remind you, this conference call is being recorded.

During this conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. Genmab is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results, unless this is required by law.

Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.

Today, I'm pleased to present Jan van de Winkel. Please begin your meeting.

Jan van de Winkel

Hello and welcome to the Genmab conference call to discuss the Company's financial results for the first half of 2022.

With me today to present these results is our CFO, Anthony Pagano. And then, for the Q&A, we will be joined by our Chief Development Officer, Judith Klimovsky; our Chief Operating Officer, Anthony Mancini; and our Chief Medical Officer, Tahi Ahmadi. Let's move to slide 2.

As already said, we will be making forward-looking statements. So, please keep that in mind as we go through this call. Let's move to slide 3.

Genmab has an innovation-based culture, and collaborations and partnerships have always been part of our DNA. During today's presentation, we will reference some of the products being developed under these strategic collaborations, and this slide acknowledges those relationships. Let's now move to slide 4.

Genmab has experienced significant growth over the past few years in all areas of our business. Based on this progress, our executive committee determined that it was time to look beyond our 2025 vision for the Company to see how we can continue to impact the lives of patients and the healthcare community even further into the future.

Working with a broad cross-functional team of Genmab colleagues, we created our updated core purpose and 2030 vision that you see here. The biggest change between our 2025 and our 2030 visions is the expansion in our focus from just cancer to cancer and other diseases. We know that our antibody knowhow, assets and technologies can be applied to diseases outside of cancer. The approvals of Novartis’ Kesimpta in relapsing MS; and Horizon’s TEPEZZA in thyroid eye disease are proof of this.